REG - Synairgen plc - Results of AGM and Appointment of New Chairman

SynairgenAnnouncement

10/10/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241010:nRSJ7696Ha&default-theme=true

RNS Number : 7696H  Synairgen plc  10 October 2024

 

Synairgen plc

('Synairgen' or the 'Company')

Results of Annual General Meeting and Appointment of New Chairman

 

Southampton, UK - 10 October 2024: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, announces the
results of voting at its Annual General Meeting today. All resolutions
proposed at its Annual General Meeting were passed.

The full results of the proxy voting and text of the resolutions can be viewed
by visiting the Company's website at www.synairgen.com/investors/aim-rule-26
(http://www.synairgen.com/investors/aim-rule-26) .

Following the announcement on 18 September, Dr. Mark Parry-Billings has now
succeeded Simon Shaw as Chairman of the Board of Directors, effective
immediately post today's AGM. Dr. Parry-Billings is an accomplished
international biotech and pharmaceutical executive with a successful track
record of more than 30 years heading R&D and leading businesses. Most
recently, he served as Global Head of Drug Development at Chiesi. Prior to
this, he served as CEO of Topigen Pharmaceuticals until its acquisition by
Pharmaxis in 2010. Mark has deep expertise in respiratory therapeutics and
drug delivery to the lungs, notably having led multiple novel respiratory
assets from early stage through clinical development and to market approvals,
with a primary focus on inhaled drug delivery.

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com (mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Nigel Birks - Life Science Specialist Sales

 

Tel: + 44 (0) 20 7220 0500

 

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

synairgen@consilium-comms.com (mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com (http://www.synairgen.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEAKEEFEALFFA